^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    gataparsen (LY2181308)

    i
    Associations
    News

    Trials

    Company:
    Eli Lilly, Ionis
    Drug class:
    Survivin inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00620321)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    09/09/2019
    Initiation :
    03/01/2008
    Primary completion :
    01/01/2010
    Completion :
    01/01/2010
    BIRC5
    |
    BIRC5 expression
    |
    cytarabine • idarubicin hydrochloride • gataparsen (LY2181308)